cntn5 Antibody

What is CNTN5 and why is it significant for neuroscience research?

CNTN5 (Contactin-5) is a cell adhesion molecule belonging to the Contactin family of immunoglobulin (Ig)-CAMs that is exclusively expressed in the central nervous system. It has gained significant research attention due to its association with neurodevelopmental disorders, particularly autism spectrum disorder (ASD) . CNTN5, along with other Contactin family members (CNTN4 and CNTN6), has been implicated in ASD through copy number variation analysis . These proteins share 40-60% of their amino acid sequence but have distinct expression patterns and appear to serve unique functions in brain development . The significance of CNTN5 extends beyond ASD, as it has also been implicated in other neuropsychiatric disorders such as anorexia nervosa .

What is the expression pattern of CNTN5 in the brain?

CNTN5 exhibits a distinct spatiotemporal expression pattern in the brain. Northern blot analysis of adult human brain has revealed that CNTN5 mRNA is primarily expressed in the occipital lobe and amygdala, followed by the cerebral cortex, frontal lobe, thalamus, and temporal lobe . In rodent studies, CNTN5 is transiently expressed during the first postnatal week in glutamatergic neurons of the central auditory system, reaching maximum levels at postnatal day 14 in the cerebrum and postnatal day 3 in the cerebellum before declining thereafter .

In situ hybridization studies have demonstrated high CNTN5 mRNA expression in regions of the central auditory pathways, including the cochlear nuclei, superior olivary complex (SOC), inferior colliculi (IC), medial geniculate nuclei, and auditory cortex . Additionally, immunohistochemistry studies have revealed Cntn5 protein expression in the cerebral cortex, hippocampus, and mammillary bodies, as well as in previously described brain nuclei of the auditory pathway and dorsal thalamus .

What are the characteristic properties of commercially available CNTN5 antibodies?

Commercial CNTN5 antibodies typically exhibit specific properties designed for research applications. For example, a polyclonal CNTN5 antibody available for human samples possesses the following properties:

This information is critical for determining antibody suitability for specific experimental applications .

How should CNTN5 antibodies be stored and handled to maintain efficacy?

For optimal maintenance of antibody efficacy, CNTN5 antibodies should be stored as aliquots at -20°C to prevent protein degradation . It is crucial to avoid repeated freeze/thaw cycles as these can lead to denaturation of the antibody and reduced specificity and sensitivity . Commercial CNTN5 antibodies are typically supplied in a buffer containing PBS (without Mg²⁺ and Ca²⁺, pH 7.4), 150 mM NaCl, 0.02% sodium azide as a preservative, and 50% glycerol to prevent freezing at -20°C . When handling the antibody, researchers should follow standard laboratory practices for protein solutions, including using clean pipette tips, avoiding contamination, and maintaining sterile conditions when possible.

How can the specificity of a CNTN5 antibody be validated?

Validating CNTN5 antibody specificity is a critical step before conducting experiments. A comprehensive validation approach includes multiple methods:

• Immunocytochemistry validation: Test the antibody on cells transfected with a CNTN5 expression plasmid (positive control) against untransfected cells or cells expressing related proteins like CNTN6 (negative controls). A specific antibody will only recognize cells expressing CNTN5 .

• Western blot validation: Compare brain lysates from wild-type animals with those from CNTN5 knockout animals. A specific CNTN5 antibody will detect a band of approximately 130 kDa in wild-type samples that should be absent in knockout samples .

• Immunohistochemistry validation: Perform staining on brain sections from both wild-type and CNTN5 knockout animals. Specific staining should be present in regions known to express CNTN5 (such as inferior colliculus, superior olivary complex, and dorsal thalamus) in wild-type animals but absent in knockout animals .

• Cross-reactivity testing: Ensure the antibody does not cross-react with other Contactin family members by testing against cells expressing CNTN4 or CNTN6 .

This multi-method validation approach ensures that experimental results obtained using the antibody are truly reflective of CNTN5 expression and not artifacts or non-specific binding .

What controls should be included when using CNTN5 antibodies in immunohistochemistry?

When using CNTN5 antibodies for immunohistochemistry, several controls are essential to ensure reliable and interpretable results:

• Negative controls:

  • Tissue from CNTN5 knockout/null mutant animals to confirm antibody specificity

  • Primary antibody omission control to assess non-specific binding of secondary antibody

  • Isotype control using non-specific IgG from the same host species to evaluate background staining

• Positive controls:

  • Tissues with known CNTN5 expression (e.g., inferior colliculus, superior olivary complex, dorsal thalamus in P7 wild-type mice)

  • Comparison with mRNA expression data from in situ hybridization to confirm protein localization matches transcript expression

• Expression pattern controls:

  • If specific developmental timepoints are being examined, include samples from different ages to confirm expected temporal expression patterns (e.g., P7 for peak expression in mouse)

  • Include multiple brain regions to verify the expected spatial expression pattern

These controls help distinguish between specific and non-specific signals and provide confidence in experimental results .

How can CNTN5 antibodies be used to study neurodevelopmental disorders?

CNTN5 antibodies serve as powerful tools for investigating neurodevelopmental disorders, particularly autism spectrum disorder (ASD). Advanced methodological approaches include:

• Comparative expression analysis: Using CNTN5 antibodies to compare protein expression levels and patterns between neurotypical individuals and those with neurodevelopmental disorders. This can be done in post-mortem brain tissue or patient-derived induced pluripotent stem cell (iPSC) models .

• Cellular phenotyping: CNTN5 antibodies can be used to characterize cellular phenotypes in CNTN5 mutant models. For instance, researchers have identified thinning of the primary somatosensory (S1) cortex in CNTN5 knockout mice, which was associated with misplacement of CNTN5-ablated cells .

• Protein-protein interaction studies: CNTN5 antibodies can be employed in co-immunoprecipitation assays to identify binding partners and signaling pathways that may be disrupted in neurodevelopmental disorders.

• Functional studies in iPSC-derived neurons: CNTN5 antibodies can assess protein expression in iPSC-derived neurons from patients with CNTN5 mutations or deletions. Studies have shown that neurons with heterozygous CNTN5 deletions exhibited at least 33% reduction in CNTN5 protein levels along with increased network burst frequency, indicating more synchronized neuronal activity .

• Validation of genetic models: Researchers can use CNTN5 antibodies to verify protein reduction in genetic models, such as the StopTag insertion approach that disrupts CNTN5 gene expression .

These applications provide critical insights into the molecular mechanisms underlying neurodevelopmental disorders associated with CNTN5 dysfunction.

What methodologies can be used to quantify CNTN5 expression in brain tissue?

Quantifying CNTN5 expression in brain tissue requires sophisticated methodological approaches:

• Quantitative immunohistochemistry:

  • Fluorescence intensity measurement in specific brain regions

  • Cell counting to determine the percentage of CNTN5-positive cells

  • Layer-specific analysis in cortical regions to detect changes in expression patterns

• Western blot quantification:

  • Densitometric analysis of CNTN5 band intensity normalized to housekeeping proteins

  • Comparison between wild-type and mutant samples to determine relative expression levels

  • Temporal expression analysis at different developmental stages

• Quantitative PCR (qPCR) with validation at protein level:

  • Determine temporal expression profiles of CNTN5 mRNA

  • Correlation of mRNA levels with protein expression using CNTN5 antibodies

  • For example, qPCR analysis has shown that CNTN5 expression peaks around birth in mice

• Single-cell analysis:

  • Immunofluorescence combined with confocal microscopy for subcellular localization

  • Co-localization with cell-type specific markers to identify CNTN5-expressing populations

  • Correlation of CNTN5 expression with neuronal morphology or electrophysiological properties

These quantitative approaches enable precise characterization of CNTN5 expression in normal development and disease states.

How can CNTN5 antibodies be used in co-localization studies with other neural markers?

Co-localization studies using CNTN5 antibodies together with other neural markers provide valuable insights into the cellular context of CNTN5 expression and function. Methodological approaches include:

• Dual/triple immunofluorescence protocols:

  • Combine CNTN5 antibodies with markers for specific neural cell types (neurons, astrocytes, oligodendrocytes)

  • Use markers for specific neuronal subtypes (e.g., glutamatergic, GABAergic, dopaminergic neurons)

  • Include markers for subcellular compartments (dendrites, axons, synapses) to determine CNTN5 localization

• Confocal microscopy analysis:

  • Z-stack imaging to confirm true co-localization in three dimensions

  • Quantification of co-localization using Pearson's or Mander's coefficients

  • High-resolution imaging of synaptic structures to examine CNTN5 at the synapse

• Sequential staining protocols:

  • When antibodies derived from the same host species must be used

  • Complete staining with the first primary-secondary antibody pair, followed by blocking with unconjugated Fab fragments before applying the second primary antibody

• Controls for co-localization studies:

  • Single-stained controls to account for bleed-through

  • Absorption controls with blocking peptides

  • Comparison with mRNA co-localization data from in situ hybridization

CNTN5 has been reported to be expressed in glutamatergic neurons of the central auditory system and other brain regions, making co-localization studies particularly informative for understanding its role in specific neural circuits .

What phenotypes are observed in CNTN5 knockout/mutant models?

CNTN5 knockout/mutant models exhibit specific phenotypes that provide insights into the functional role of this protein:

• Structural brain abnormalities:

  • Thinning of the primary somatosensory (S1) cortex in CNTN5 null mutant mice

  • Misplacement of CNTN5-ablated cells in the cortex

  • Reduction in the barrel/septa ratio of the S1 barrel field

• Neuronal network activity changes:

  • Increased network burst frequency in neurons derived from patients with heterozygous CNTN5 deletions

  • More synchronized neuronal activity across neural networks

  • These electrophysiological phenotypes may only become apparent at later developmental stages (e.g., week 10 in some isogenic models)

• Protein expression alterations:

  • At least 33% reduction in CNTN5 protein levels in heterozygous mutants

  • Evidence that the non-deleted allele may become more transcriptionally active in heterozygous models

• Preserved structures and behaviors:

  • Intact structure and morphology of the hippocampus despite CNTN5 expression in this region

  • Surprisingly, social, exploratory, and repetitive behaviors appear unaffected in CNTN5 null mutant mice

These findings suggest that CNTN5 plays a selective role in cortical development without causing overt behavioral abnormalities in mice, highlighting the complexity of translating molecular and cellular phenotypes to behavioral outcomes.

How can the temporal expression pattern of CNTN5 be studied during development?

Studying the temporal expression pattern of CNTN5 during development requires a combination of approaches:

• Quantitative PCR (qPCR) time course:

  • Analyze CNTN5 mRNA levels at different developmental stages

  • Research has shown that CNTN5 levels peak around birth in mice

  • Sample collection at embryonic, early postnatal, juvenile, and adult stages to capture the complete temporal profile

• Immunohistochemistry series:

  • Apply CNTN5 antibodies to brain sections from animals at different developmental ages

  • CNTN5 expression has been reported to reach maximum levels at postnatal day 14 in the cerebrum and postnatal day 3 in the cerebellum, declining thereafter

  • Compare expression patterns across different brain regions at each timepoint

• Western blot developmental series:

  • Quantify CNTN5 protein levels in brain lysates collected at different ages

  • Normalize to housekeeping proteins that remain stable throughout development

  • Plot expression trends to identify critical periods of CNTN5 function

• In situ hybridization with protein validation:

  • Compare mRNA localization with protein expression at key developmental timepoints

  • Create detailed tables comparing mRNA and protein localization across brain regions

This comprehensive approach provides insights into the dynamic regulation of CNTN5 during critical periods of neural development .

What is the relationship between CNTN5 expression and auditory system development?

The relationship between CNTN5 expression and auditory system development is particularly significant:

• Spatial expression in auditory pathways:

  • CNTN5 is highly expressed in regions of the central auditory system, including the cochlear nuclei, superior olivary complex (SOC), inferior colliculi (IC), medial geniculate nuclei, and auditory cortex

  • Immunohistochemistry reveals CNTN5 presence in bushy neurons of the ventral cochlear nucleus (VCN) and in the ventral acoustic stria

• Developmental timing:

  • CNTN5 is transiently expressed during the first postnatal week in glutamatergic neurons of the central auditory system

  • CNTN5 immunoreactivity is present in the glutamatergic presynaptic terminals at the lateral superior olive (LSO) and the calyces of Held in the medial nucleus of the trapezoid body (MNTB) at the finalization of auditory brainstem development

  • Between P1 and P7, CNTN5 is transiently expressed in glutamatergic synapses of the VCN and SOC, during the period of completion of young calyces

• Functional implications:

  • The temporal expression pattern coincides with synapse formation and myelination in the central nervous system

  • This suggests a role for CNTN5 in the establishment of functional auditory circuits

  • The precise temporal regulation indicates that CNTN5 may be involved in specific developmental events in auditory system maturation

• Methodological approaches:

  • Use CNTN5 antibodies in combination with auditory system-specific markers to study co-localization

  • Perform functional assays in CNTN5-deficient models to assess auditory processing

  • Combine morphological studies with electrophysiological recordings to correlate CNTN5 expression with functional development of auditory circuits

Understanding this relationship provides insights into both normal auditory system development and potential mechanisms underlying hearing-related disorders associated with CNTN5 dysfunction.

What are common technical challenges when using CNTN5 antibodies and how can they be addressed?

Researchers working with CNTN5 antibodies may encounter several technical challenges:

• Background staining issues:

  • Challenge: High background in immunohistochemistry or immunocytochemistry

  • Solution: Optimize blocking conditions (try different blocking agents such as BSA, normal serum, or commercial blocking solutions); increase blocking time; reduce primary antibody concentration; use more stringent washing steps; consider antigen retrieval optimization

• Antibody specificity concerns:

  • Challenge: Cross-reactivity with other Contactin family members due to 40-60% sequence homology

  • Solution: Validate antibody specificity using CNTN5 knockout tissue as negative control; perform absorption controls with recombinant CNTN5 protein; test for cross-reactivity with other Contactins in overexpression systems

• Temporal expression variability:

  • Challenge: CNTN5 expression varies significantly across developmental stages

  • Solution: Determine optimal timepoints for analysis (e.g., P7 for peak expression in mice); conduct preliminary time-course experiments; adjust antibody concentration for different developmental stages

• Fixation sensitivity:

  • Challenge: Some epitopes may be sensitive to fixation conditions

  • Solution: Compare different fixation methods (PFA, methanol, acetone); optimize fixation duration; consider post-fixation antigen retrieval methods

• Antibody penetration in thick sections:

  • Challenge: Difficulty achieving uniform staining in thick tissue sections

  • Solution: Extend incubation times; use detergents to enhance penetration; consider vibratome sections instead of cryosections; use tissue clearing techniques for 3D imaging

Addressing these challenges requires systematic optimization and inclusion of appropriate controls to ensure reliable and reproducible results.

How should experimental design be adjusted when comparing CNTN5 expression across different brain regions?

When comparing CNTN5 expression across different brain regions, several methodological considerations should guide experimental design:

• Reference atlas alignment:

  • Use standardized brain atlases to ensure accurate identification of regions

  • Document precise coordinates and anatomical landmarks for reproducibility

  • Consider stereotaxic approaches for consistency across samples

• Sampling strategy:

  • Employ systematic random sampling to avoid bias

  • Analyze multiple sections per region (minimum 3-5 sections)

  • Include multiple animals (minimum n=3-5) to account for biological variability

  • Control for age and sex differences that may affect CNTN5 expression

• Quantification approaches:

  • Use consistent parameters for image acquisition across all regions

  • Establish objective thresholds for signal detection

  • Employ unbiased stereological methods when appropriate

  • Consider both cell density and signal intensity measurements

  • Normalize to region volume or cell number to account for size differences

• Controls for regional variation:

  • Include positive control regions with known high CNTN5 expression (e.g., auditory nuclei)

  • Include negative control regions with minimal CNTN5 expression

  • Use internal controls within each section when possible

• Technical considerations:

  • Process all samples simultaneously to minimize batch effects

  • Use automated staining systems if available to reduce variability

  • Consider region-specific fixation effects and optimize accordingly

  • Account for differences in antibody penetration between regions with varying cell densities

By addressing these methodological considerations, researchers can obtain reliable comparative data on CNTN5 expression across brain regions.

What are the best practices for quantifying CNTN5 protein reduction in knockout or knockdown models?

Accurate quantification of CNTN5 protein reduction in knockout or knockdown models requires rigorous methodological approaches:

• Western blot quantification:

  • Sample preparation: Use consistent protein extraction protocols and determine protein concentration by BCA or Bradford assay

  • Loading controls: Include multiple housekeeping proteins (e.g., β-actin, GAPDH, tubulin) to normalize loading

  • Quantification: Perform densitometric analysis using linear range exposures

  • Replication: Run at least 3-4 biological replicates and multiple technical replicates

  • Statistical analysis: Use appropriate statistical tests to determine significance of protein reduction

• Immunohistochemistry-based quantification:

  • Image acquisition: Use identical microscope settings across all samples

  • Region selection: Analyze matched anatomical regions between control and knockout animals

  • Measurement parameters: Assess both signal intensity and percentage of CNTN5-positive cells

  • Automated analysis: Employ automated image analysis algorithms to reduce bias

  • Comparison with wild-type: Always include wild-type controls processed simultaneously

• Validation in heterozygous models:

  • Expected reduction: Heterozygous models typically show approximately 50% protein reduction, but can vary

  • Allelic compensation: Check for compensatory upregulation of the remaining allele

  • Spatial specificity: Assess whether protein reduction is uniform across brain regions

• Protein knockdown verification:

  • In CNTN5 knockdown or StopTag insertion models, protein levels should be reduced by at least 33%

  • Compare protein reduction to mRNA levels using qPCR

  • Assess functional consequences of protein reduction using appropriate assays

• Artifacts and pitfalls:

  • Be aware of non-specific antibody binding that may confound results

  • Account for developmental timing, as CNTN5 expression varies throughout development

  • Consider that complete protein elimination may require time after genetic modification

These best practices ensure reliable quantification of CNTN5 protein reduction, enabling accurate interpretation of phenotypes observed in knockout or knockdown models.